Anna Johnston

1.3k total citations
38 papers, 338 citations indexed

About

Anna Johnston is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Anna Johnston has authored 38 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 14 papers in Oncology and 11 papers in Genetics. Recurrent topics in Anna Johnston's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Viral-associated cancers and disorders (7 papers). Anna Johnston is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Viral-associated cancers and disorders (7 papers). Anna Johnston collaborates with scholars based in Australia, United States and New Zealand. Anna Johnston's co-authors include Eric Uren, Gilles Salles, Luke Coyle, David Nevell, Patricia Walker, Huyen Tran, Stephen Opat, Bertrand Coiffier, Sanjeev Chunilal and John Catalano and has published in prestigious journals such as Blood, Solar Energy and SLEEP.

In The Last Decade

Anna Johnston

32 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Johnston Australia 12 129 114 73 69 63 38 338
Uta Brunnberg Germany 10 120 0.9× 133 1.2× 94 1.3× 106 1.5× 61 1.0× 23 345
Qingsong Yin China 8 97 0.8× 156 1.4× 56 0.8× 79 1.1× 108 1.7× 66 320
Annunziata Manna Italy 10 228 1.8× 174 1.5× 139 1.9× 59 0.9× 98 1.6× 29 485
Hien Liu United States 11 153 1.2× 449 3.9× 144 2.0× 156 2.3× 49 0.8× 62 594
Oscar C Estalilla United States 7 116 0.9× 109 1.0× 20 0.3× 38 0.6× 54 0.9× 12 326
Colin Phipps Diong Singapore 6 50 0.4× 94 0.8× 46 0.6× 54 0.8× 29 0.5× 23 278
Jarosław Dybko Poland 12 78 0.6× 119 1.0× 116 1.6× 93 1.3× 43 0.7× 44 344
Elizabeth Brém United States 10 93 0.7× 112 1.0× 36 0.5× 86 1.2× 40 0.6× 35 270
A. Berer Austria 10 146 1.1× 99 0.9× 91 1.2× 76 1.1× 60 1.0× 13 448

Countries citing papers authored by Anna Johnston

Since Specialization
Citations

This map shows the geographic impact of Anna Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Johnston more than expected).

Fields of papers citing papers by Anna Johnston

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Johnston. The network helps show where Anna Johnston may publish in the future.

Co-authorship network of co-authors of Anna Johnston

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Johnston. A scholar is included among the top collaborators of Anna Johnston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Johnston. Anna Johnston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shand, Antonia, Joanne Said, Kim Hobbs, et al.. (2025). Haematological malignancies during pregnancy: a systematic review of necessary services in the Australian context. Internal Medicine Journal. 55(3). 393–406.
2.
Wellard, Cameron, Allison Barraclough, Belinda A. Campbell, et al.. (2025). Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review. Blood Advances. 9(9). 2275–2284.
3.
Khong, Tiffany, Abir Khaled, John Reynolds, et al.. (2024). Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma. Haematologica. 110(3). 764–767. 2 indexed citations
4.
Tobin, Joshua W.D., Greg Hapgood, Anna Johnston, et al.. (2024). Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 54(8). 1384–1395. 2 indexed citations
5.
6.
Wellard, Cameron, Geoffrey Chong, Tara Cochrane, et al.. (2024). Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Internal Medicine Journal. 54(7). 1223–1227.
7.
Minson, Adrian, Nada Hamad, Dipti Talaulikar, et al.. (2023). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology. 204(2). 548–554. 3 indexed citations
8.
Verner, Emma, Anna Johnston, Eliza A. Hawkes, et al.. (2023). Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL. Hematological Oncology. 41(S2). 426–427. 1 indexed citations
9.
Weinkove, Robert, et al.. (2023). Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey. European Journal Of Haematology. 112(4). 621–626. 2 indexed citations
10.
11.
Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations
12.
Gritti, Giuseppe, Paula Marlton, Tycel Phillips, et al.. (2020). Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood. 136(Supplement 1). 45–47. 16 indexed citations
13.
Lee, Adrian Y. S., et al.. (2017). Clinical use and interpretation of serum protein electrophoresis and adjunct assays. British Journal of Hospital Medicine. 78(2). C18–C20. 10 indexed citations
14.
Johnston, Anna, Florence Broussais‐Guillaumot, Anne‐Sophie Michallet, et al.. (2009). Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leukemia & lymphoma. 51(3). 399–405. 19 indexed citations
15.
Johnston, Anna, Gilles Salles, Daniel Espinouse, et al.. (2008). Epstein-Barr Virus—Induced Lymphoproliferative Disorder After Rituximab Combined with CHOP Therapy. Clinical Lymphoma & Myeloma. 8(6). 356–358. 6 indexed citations
16.
Johnston, Anna & Gilles Salles. (2008). Prognostic Systems for Lymphomas. Hematology/Oncology Clinics of North America. 22(5). 839–861. 11 indexed citations
17.
Johnston, Anna, et al.. (2007). Use of a functional assay to diagnose protein S deficiency; inappropriate testing yields equivocal results. Internal Medicine Journal. 37(6). 409–411. 9 indexed citations
18.
Johnston, Anna, Luke Coyle, & David Nevell. (2005). Prolonged remission of refractory lymphomatoid granulomatosisafter autologous hemopoietic stem cell transplantation with post-transplantation maintenance interferon. Leukemia & lymphoma. 47(2). 323–328. 16 indexed citations
19.
Johnston, Anna, et al.. (2003). Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Biologicals. 31(3). 213–221. 29 indexed citations
20.
Johnston, Anna, et al.. (2000). The Use of Chromatography to Manufacture Purer and Safer Plasma Products. Biotechnology and Genetic Engineering Reviews. 17(1). 37–70. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uta Brunnberg Breakdown of academic impact, for papers by Qingsong Yin Breakdown of academic impact, for papers by Annunziata Manna Breakdown of academic impact, for papers by Hien Liu Breakdown of academic impact, for papers by Oscar C Estalilla Breakdown of academic impact, for papers by Colin Phipps Diong Breakdown of academic impact, for papers by Jarosław Dybko Breakdown of academic impact, for papers by Elizabeth Brém Breakdown of academic impact, for papers by A. Berer
Rankless by CCL
2026